CNS Pharmaceuticals Inc.

AI Score

XX

Unlock

3.77
0.15 (4.14%)
At close: Mar 21, 2025, 3:59 PM
3.71
-1.67%
After-hours: Mar 21, 2025, 07:03 PM EDT
4.14%
Bid 3.65
Market Cap 10.33M
Revenue (ttm) 785.9
Net Income (ttm) -2.11M
EPS (ttm) 2460.99
PE Ratio (ttm) n/a
Forward PE -0.27
Analyst Buy
Ask 3.79
Volume 103,668
Avg. Volume (20D) 644,447
Open 3.44
Previous Close 3.62
Day's Range 3.43 - 3.80
52-Week Range 2.00 - 975.00
Beta 1.12

About CNSP

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson...

Industry Biotechnology
Sector Healthcare
IPO Date Nov 8, 2019
Employees 3
Stock Exchange NASDAQ
Ticker Symbol CNSP
Full Company Profile

Analyst Forecast

According to 1 analyst ratings, the average rating for CNSP stock is "Buy." The 12-month stock price forecast is $25, which is an increase of 563.13% from the latest price.

Stock Forecasts
3 weeks ago
+2.53%
CNS Pharmaceuticals shares are trading higher afte... Unlock content with Pro Subscription
1 month ago
-41.23%
CNS Pharmaceuticals shares are trading lower after the company announced a 1-for-50 reverse stock split.